Christopher, Mark
Belghith, Akram
Bowd, Christopher
Proudfoot, James A.
Goldbaum, Michael H.
Weinreb, Robert N.
Girkin, Christopher A.
Liebmann, Jeffrey M.
Zangwill, Linda M.
Article History
Received: 28 August 2018
Accepted: 29 October 2018
First Online: 12 November 2018
Competing Interests
: Dr. Robert N. Weinreb received compensation as a consultant from Aerie Pharmaceuticals and Allergan. He received research support from Carl Zeiss Meditec, CenterVue, Genentech, Heidelberg Engineering, Konan Medical, the National Eye Institute, Optos, Optovue, and Research to Prevent Blindness. Dr. Christopher A. Girkin received research support from EyeSight Foundation of Alabama, Heidelberg Engineering, the National Eye Institute, and Research to Prevent Blindness. Dr. Jeffrey M. Liebman received compensation as a consultant from Alcon, Allergan, Bausch & Lomb, Carl Zeiss Meditec, Heidelberg Engineering, Reichert Technologies, and Valeant Pharmaceuticals. He received research support from Bausch & Lomb, Carl Zeiss Meditec, Heidelberg Engineering, the National Eye Institute, Optovue, Reichert Technologies, and Research to Prevent Blindness. Dr. Linda M. Zangwill received research support from Carl Zeiss Meditec, Heidelberg Engineering, the National Eye Institute, Optovue, and Topcon Medical Systems. Dr. Mark Christopher, Akram Belghith, Christopher Bowd, and Michael H. Goldbaum have no competing interests to declare.